Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Other financing activities (2019 - 2023)

Eton Pharmaceuticals' Other financing activities history spans 4 years, with the latest figure at -$1000.0 for Q4 2023.

  • For Q4 2023, Other financing activities changed N/A year-over-year to -$1000.0; the TTM value through Dec 2023 reached $180000.0, changed N/A, while the annual FY2023 figure was $180000.0, N/A changed from the prior year.
  • Other financing activities for Q4 2023 was -$1000.0 at Eton Pharmaceuticals, down from $181000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.0 million in Q3 2021 and bottomed at -$1000.0 in Q4 2023.
  • The 4-year median for Other financing activities is $605000.0 (2019), against an average of $573214.3.
  • The largest annual shift saw Other financing activities increased 5.8% in 2020 before it skyrocketed 84.38% in 2021.
  • A 4-year view of Other financing activities shows it stood at $501000.0 in 2019, then surged by 54.29% to $773000.0 in 2020, then increased by 11.64% to $863000.0 in 2021, then plummeted by 100.12% to -$1000.0 in 2023.
  • Per Business Quant, the three most recent readings for ETON's Other financing activities are -$1000.0 (Q4 2023), $181000.0 (Q1 2023), and $863000.0 (Q4 2021).